An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
The immunogenicity and safety of a meningococcal trivalent A/C/W135 polysaccharide vaccine was compared with that of a tetravalent A/C/Y/W135 polysaccharide vaccine in a randomised, double blind trial. The study included 360 adults, who received either a trivalent or tetravalent polysaccharide meningococcal vaccine. Antibody responses were determined by serum bactericidal antibody (rSBA) assays prior to vaccination and on day 28 and month 11 after vaccination. The percentage of participants in the trivalent vaccine group who had rSBA titres >or=8 on day 28 post-vaccination against serogroups A, C and W135 meningococci were 99, 98 and 91%, respectively. The corresponding figures in the tetravalent vaccine group were 99, 99 and 90%. The percentage of participants with various cut off levels of rSBA against serogroups A, W135 and C meningococci on day 28 and 11-month post-vaccination and the incidence of adverse events did not differ significantly between the two groups.
Chandramohan
Daniel
D
London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Daniel.chandramohan@lshtm.ac.uk
Hodgson
Abraham
A
Coleman
Paul
P
Baiden
Rita
R
Asante
Kwaku
K
Awine
Elizabeth
E
Owusu-Agyei
Seth
S
Boutriau
Dominique
D
Nelson
Christopher B
CB
Greenwood
Brain
B
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D008585:Meningitis, Meningococcal / Q000097:blood / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D038582:Neisseria meningitidis, Serogroup W-135 / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D015610:Serum Bactericidal Test / Q000379:methods; D016896:Treatment Outcome
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial